SEARCH

SEARCH BY CITATION

References

  • 1
    Jansen J.B. & Van Oene J.C. Part of the results have been presented at the fall meeting of the Nederlandse Vereniging voor Gastroenterologie October 5–6. Veldhoven, The Netherlands, and at the annual meeting of the American Gastroenterological Association, May 19–22, 1996, San Francisco, California, 1995.
  • 2
    Tytgat GNJ, Nio CY, Schotborgh RH. Reflux esophagitis. Scand J Gastroenterol 1990; 25: 1 12.
  • 3
    Klinkenberg-Knol EC, Jansen JBMJ, Festen HPM, Meuwissen SGM, Lamers CBHW. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987; i: 349 51.
  • 4
    Vantrappen G, Rutgeerts L, Schurmans PR, Coenegrachts JL. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33: 523 9.
  • 5
    Bardhan KD, Hawkey CJ, Long RG, et al., on behalf of the UK Lansoprazole Clinical Research Group. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1995; 9: 145 51.
  • 6
    Castell DO & Johnston BT. Gastroesophageal reflux disease. Current strategies for patient management. Arch Fam Med 1996; 5: 221 7.
  • 7
    Jansen JBMJ, Baak LC, Lamers CBHW. Effect of increasing doses of ranitidine on exposure of the oesophagus to gastric acid in patients with reflux oesophagitis. Scand J Gastroenterol 1988; 23: 2 5.
  • 8
    Johnson NJ, Boyd EJS, Mills JG, Wood JR. Acute treatment of reflux oesophagitis: a multi-centre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989; 3: 259 66.
  • 9
    Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225 50.
  • 10
    Savary M & Miller G. The Esophagus. Handbook and Atlas of Endoscopy. Solothurn, Switzerland: Grassmann, 1977: 135.
  • 11
    Reynolds JEF, ed. Martindale. The Extra Pharmacopoeia. 31st Edition. London: Royal Pharmaceutical Society of Great Britain, 1996: 1237–9.
  • 12
    Koelz HR, Birchler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198 205.
  • 13
    Thomson ABR, Babiuk L, Kirdeikis P, Zuk L, Marriage B, Bowes K. A dose-ranging study of ranitidine and its effect on intragastric and intra-oesophageal acidity in subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1994; 8: 443 51.
  • 14
    Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, Page JG. The effects of lansoprazole, a new H+, K+-ATPase inhibitor, on gastric pH and serum gastrin . Aliment Pharmacol Ther 1992; 6: 359 72.
  • 15
    Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P, The Lansoprazole Study Group. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol 1994; 89: 1191 200.
  • 16
    Jones RH & Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11: 541 6.
  • 17
    Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25 31.
  • 18
    Primrose JN, Rogers MJ, Holmfield JHM. The effects of 300 mg ranitidine at night, twice daily and four times daily on intragastric acidity in normal subjects. Aliment Pharmacol Ther 1993; 7: 287 91.
  • 19
    Lundell L, Backman L, Ekström P, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ‘standard doses’ of H2-receptor antagonists . Aliment Pharmacol Ther 1990; 4: 145 55.
  • 20
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798 810.
  • 21
    Sontag SJ, Schnell TG, Chejfec G, Kurucar C, Karpf J, Levine G. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett’s oesophagus. Aliment Pharmacol Ther 1997; 11: 147 56.
  • 22
    Hurlimann S, Abbühl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193 201.
  • 23
    Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion – tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013 8.
  • 24
    Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65 70.
  • 25
    Bell NJV & Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther 1996; 10: 897 904.
  • 26
    Mee AS & Rowley JL, The Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757 63.
  • 27
    Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993; 28: 224 8.
  • 28
    Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM, The Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749 57.
  • 29
    Hedenström H, Alm C, Kraft M, Grahnén A. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997; 11: 1137 41.
  • 30
    Spencer CM & Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404 30.
  • 31
    Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35: 23 6.
  • 32
    Lewis SJ, Franco S, Young G, O’Keefe SJD. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996; 10: 557 61.
  • 33
    Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54 9.
  • 34
    Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy . Am J Gastroenterol 1997; 92: 429 37.
  • 35
    Unge P, Gad A, Eriksson K, et al.Amoxycillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993; 5: 325 31.
  • 36
    Beker JA, Bianchi Porro G, Bigard MA, et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 407 10.
  • 37
    Breuer T, Kim JG, Gurer IE, et al. Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 523 7.